Clinical Trial Update: PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating panitumumab added to regimen for metastatic or recurrent squamous cell carcinoma of the head and neck has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2014-02-07